Finance

Beta
Lists
BCAX:NASDAQ
Bicara Therapeutics Inc
$30.40
+4.04%
(+1.18) 1D
$30.50
+0.33% (+0.10)
Pre-market
Closed: Jul 7, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BCAX...
Open
$29.45
High
$30.99
Low
$29.06
Mkt. cap
2.00B
Avg. vol.
824.45K
Volume
314.00
52-wk high
$30.99
52-wk low
$8.98
EPS
-$2.77
Shares outstanding
65.70M
No. of employees
103
Open
$29.45
High
$30.99
Low
$29.06
Mkt. cap
2.00B
Avg. vol.
824.45K
Volume
314.00
52-wk high
$30.99
52-wk low
$8.98
EPS
-$2.77
Shares outstanding
65.70M
No. of employees
103
News stories
From sources across the web
About Bicara Therapeutics Inc
CEO-
Employees103
Founded2018
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitebicara.com
Analyst ratings
Based on 11 analysts giving stock ratings to BCAX in the past 3 months
Strong buy
Buy
9
Hold
2
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for BCAX in the last 3 months.
Highest
Current $30.40
$46.00 (+51.32%)
Average
$32.11 (+5.63%)
Lowest
$16.00 (-47.37%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
-
-
06/02/2026
Rajan Sharma
Goldman Sachs
Hold
Maintained
$18.00
-40.8%
06/01/2026
Richard Law CFA
Goldman Sachs
Hold
Maintained
$18.00
-40.8%
06/01/2026
Eva Fortea Verdejo
Wells Fargo
Hold
Reiterated
$16.00
-47.4%
06/01/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$42.00
+38.2%
06/01/2026
Unknown Analyst
Wedbush
Buy
Maintained
$30.00
-1.3%
05/26/2026
Bradley Canino
Guggenheim
Buy
Maintained
$42.00
+38.2%
05/26/2026
Boris Peaker
JonesTrading
Buy
Maintained
$30.00
-1.3%
05/22/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$46.00
+51.3%
05/12/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$37.00
+21.7%
05/12/2026
Jeet Mukherjee
BTIG
Buy
Reiterated
$28.00
-7.9%
05/11/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
Soumit Roy
JonesTrading
Buy
Maintained
$30.00
-1.3%
04/06/2026
Reni Benjamin
Citizens JMP
Buy
Initiated
$31.00
+2%
01/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
24.80M
32.98M
32.99M
47.50M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.22M
7.70M
8.13M
12.74M
Operating expense
32.02M
40.68M
41.12M
60.24M
Total operating expenses
32.02M
40.68M
41.12M
60.24M
Operating income
-32.02M
-40.68M
-41.12M
-60.24M
Other non operating income
-
-
-
-
EBT including unusual items
-27.34M
-36.29M
-37.33M
-56.16M
EBT excluding unusual items
-27.34M
-36.29M
-37.33M
-56.16M
Income tax expense
52.00K
40.00K
53.00K
52.00K
Effective tax rate
-0.19%
-0.11%
-0.14%
-0.09%
Other operating expenses
-
-
-
-
Net income
-27.39M
-36.33M
-37.39M
-56.21M
Net profit margin
-
-
-
-
Earnings per share
-0.50
-0.67
-0.68
-0.93
Interest and investment income
4.68M
4.39M
3.79M
4.08M
Interest expense
-
-
-
-
Net interest expenses
4.68M
4.39M
3.79M
4.08M
Depreciation and amortization charges
-
-
-
-
EBITDA
-32.00M
-40.65M
-41.08M
-60.20M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer